FDA Issues Complete Response Letter for Joenja® sNDA in Pediatric APDS
PHAR has more than doubled off its 52-week low of $7.502.
Summary
Pharming Group received a Complete Response Letter from the FDA for its sNDA for Joenja® in children aged 4-11 with APDS, citing issues with pediatric dosing data and an analytical method, delaying market expansion.
Key Events · Product Development and Regulatory · PHAR
-
FDA Issues Complete Response Letter
The U.S. FDA issued a CRL for the sNDA of Joenja® (leniolisib) for children aged 4-11 years with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS).
-
Reasons for Delay
The CRL cited concerns about potential underexposure in lower-weight pediatric patients, requiring additional pharmacokinetic data, and an issue with an analytical method used for production batch testing.
-
Existing Approval Unaffected
The current FDA approval for Joenja® in patients aged 12 years and older for APDS remains unaffected by this regulatory action.
-
Company Response
Pharming Group plans to address the identified issues, work closely with the FDA, and request a Type A meeting to determine next steps for resubmission.
Analysis · PHAR · Life Sciences
The U.S. FDA's Complete Response Letter (CRL) for Joenja®'s supplemental New Drug Application (sNDA) for children aged 4-11 with APDS represents a setback for Pharming Group. While the existing approval for patients 12 and older remains unaffected, this CRL delays market expansion into a younger pediatric population. The FDA cited concerns regarding potential underexposure in lower-weight pediatric patients, requiring additional pharmacokinetic data, and an issue with an analytical method. The company's plan to address these issues and request a Type A meeting indicates a path forward, but it will incur additional time and resources before potential approval for this indication.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $17.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.50 to $21.34. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.